Skip to main navigation
Syndax Pharmaceuticals, Inc. logo
  • Contact Us
  • About Us
    • About Us
    • Leadership
    • Board of Directors
    • Patient Community
  • Focus Areas
    • Focus Areas
    • KMT2Ar Acute Leukemias
    • NPM1m Acute Myeloid Leukemia
    • Chronic Graft-Versus-Host Disease
  • Pipeline
    • Pipeline
    • Menin Inhibitor
    • Anti-CSF-1R Monoclonal Antibody
    • Entinostat
    • Publications & Meeting Presentations
  • Our Products
  • Patients
    • Patients
    • Compassionate Use
  • Investors
  • Careers
  • News
  • Contact Us

Press Releases

Investors
  • Home
  • Press Releases
  • Events & Presentations
  • Corporate Governance
    • Governance Overview
    • Management
    • Board of Directors
    • Committee Composition
    • Contact the Board
  • Financial Information
    • Financial Overview
    • SEC Filings
    • Annual Reports and Proxies
    • Quarterly Results
    • Key Ratios
  • Stock Information
    • Stock Quote & Chart
    • Historic Stock Lookup
    • Analyst Coverage
  • Shareholder Services
    • Investor FAQs
    • Contact Us
    • RSS Feeds
    • Email Alerts
04.13.07
Syndax Pharmaceuticals Inc. Licenses Selective Histone Deacetylase Inhibitor MS-275

Clinical oncology compound already tested in over 200 patients

Read More
04.03.07
Syndax Pharmaceuticals Inc. closes $40 Million Series A Financing

Funds to support pipeline development

Read More
  • First page «
  • Previous page ‹
  • …
  • Page 25
  • Page 26
  • Current page 27
Syndax Pharmaceuticals, Inc. logo
  • About Us
  • Focus Areas
  • Pipeline
  • Our Products
  • Patients
  • Investors
  • Careers
  • News
  • Contact Us
Privacy Notice
Cookie Notice
Consumer Health Data Supplemental Privacy Notice
State Regulations
Terms of Use
Limit the Use of My Personal Information
© 2025 Syndax Pharmaceuticals, Inc.
linkedin x.com glassdoor